We may earn a commission when readers sign up through partner links. Rankings reflect our published methodology, not advertiser fees.
GLP·Agonists Editor's Pick

Condition · Evidence Review

GLP-1 Agonists and Type 2 Diabetes: A1c, CV Benefit, Guidelines

Fact-checked by Dr. Adam Kennah, MD on . See our fact-checking policy.

GLP-1 receptor agonists are first-line second-step therapy in type 2 diabetes after metformin. The class lowers A1c by 1.0–2.0%, drives meaningful weight loss, has very low hypoglycemia risk as monotherapy, and — for semaglutide and dulaglutide — reduces major adverse cardiovascular events in adults with established disease.

Key facts

  • A1c reduction: 1.0–1.8% with semaglutide; 1.8–2.4% with tirzepatide (head-to-head SURPASS trials).
  • Weight loss: 4–7 kg with semaglutide 1 mg; 7–12 kg with tirzepatide at higher doses.
  • Hypoglycemia: Very low risk as monotherapy. Risk rises when combined with sulfonylureas or insulin — those should be reduced at initiation.
  • CV benefit: Demonstrated for semaglutide (SUSTAIN-6), dulaglutide (REWIND), liraglutide (LEADER). Tirzepatide CV trial (SURPASS-CVOT) results expected 2026.

Why ADA guidelines moved GLP-1s up the algorithm

The 2023 ADA Standards of Care now recommend GLP-1 RAs (or SGLT2 inhibitors) as preferred second-line agents for patients with T2D and either established cardiovascular disease, heart failure, or chronic kidney disease — independent of A1c. This is a shift from the older "A1c-first" algorithm and reflects the strength of cardiovascular and renal outcome data.

Mechanism in T2D specifically

In T2D, GLP-1 agonists work through four parallel mechanisms:

  1. Glucose-dependent insulin secretion — the alpha cell only releases insulin when serum glucose is elevated, which is why hypoglycemia risk is low.
  2. Glucagon suppression — postprandial glucagon falls, reducing hepatic glucose output.
  3. Delayed gastric emptying — flattens the postprandial glucose curve.
  4. Central appetite suppression — drives the weight loss, which independently improves insulin sensitivity.

Choosing an agent

For most patients with T2D, the practical choice is between semaglutide (Ozempic) and tirzepatide (Mounjaro). Tirzepatide is more potent on both A1c and weight, but cardiovascular outcome data is still pending. Semaglutide has the largest body of evidence and FDA-approved CV indication.

What compounded versions can and cannot do

Compounded semaglutide and tirzepatide deliver the same active molecule. They are not FDA-approved for any indication, including diabetes. The clinical decision to use a compounded preparation in a T2D patient should consider insurance coverage of brand product, glycemic targets, and patient access. Compounded GLP-1s are typically prescribed for weight management, not for primary diabetes management when brand-name product is available.

Insurance and access

Ozempic and Mounjaro are covered by most commercial plans and Medicare Part D for the T2D indication. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide for obesity) are weight-management indications and frequently excluded. See our insurance coverage guide.

References

For detailed citations, see our research bibliography — SUSTAIN-6, REWIND, LEADER, SURPASS-1 through SURPASS-5 are the primary T2D trials.